Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

about

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Item

http://www.wikidata.org/entity/Q48211870

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@en

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@nl

type

Item

label

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@en

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@nl

prefLabel

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@en

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@nl

P1476

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

@en

P2093

Bethany Qiang

http://www.w3.org/2001/XMLSchema#string

Billie Nowak

http://www.w3.org/2001/XMLSchema#string

Nancy Cheng

http://www.w3.org/2001/XMLSchema#string

Xiaojun Liu

http://www.w3.org/2001/XMLSchema#string

Yingjun Jiang

http://www.w3.org/2001/XMLSchema#string

Yuling Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Sapacitabine for cancer

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Resistance to therapy caused by intragenic deletion in BRCA2

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Ovarian cancer development and metastasis.

Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

P2888

s00280-017-3483-6

P304

255-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3483-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Plunkett

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29189915

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5777892

http://www.w3.org/2001/XMLSchema#string